Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12
- PMID: 16817690
- DOI: 10.3171/foc.2000.9.6.8
Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12
Abstract
Object: The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved.
Methods: Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-12, and SFV-IL12, respectively. The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity.
Conclusions: Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines.
Similar articles
-
Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.J Neurosurg. 2002 Sep;97(3):611-8. doi: 10.3171/jns.2002.97.3.0611. J Neurosurg. 2002. PMID: 12296646
-
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.J Neurosurg. 2001 Mar;94(3):474-81. doi: 10.3171/jns.2001.94.3.0474. J Neurosurg. 2001. PMID: 11235953
-
Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.J Neurosurg. 2003 Oct;99(4):746-53. doi: 10.3171/jns.2003.99.4.0746. J Neurosurg. 2003. PMID: 14567611
-
Semliki Forest virus vectors for gene therapy.Expert Opin Biol Ther. 2003 Aug;3(5):771-7. doi: 10.1517/14712598.3.5.771. Expert Opin Biol Ther. 2003. PMID: 12880377 Review.
-
Semliki Forest virus-based immunotherapy for cancer.Expert Opin Biol Ther. 2020 Jun;20(6):593-599. doi: 10.1080/14712598.2020.1727438. Epub 2020 Feb 13. Expert Opin Biol Ther. 2020. PMID: 32050824 Review.
Cited by
-
Replicon RNA Viral Vectors as Vaccines.Vaccines (Basel). 2016 Nov 7;4(4):39. doi: 10.3390/vaccines4040039. Vaccines (Basel). 2016. PMID: 27827980 Free PMC article. Review.
-
Alphavirus-based vaccines.Viruses. 2014 Jun 16;6(6):2392-415. doi: 10.3390/v6062392. Viruses. 2014. PMID: 24937089 Free PMC article. Review.
-
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.Mol Ther. 2012 Sep;20(9):1664-1675. doi: 10.1038/mt.2012.56. Epub 2012 Jun 26. Mol Ther. 2012. PMID: 22735380 Free PMC article.
-
Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.J Neurooncol. 2003 Aug-Sep;64(1-2):147-54. doi: 10.1007/BF02700029. J Neurooncol. 2003. PMID: 12952295 Clinical Trial.
-
Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies.Pharmaceutics. 2022 Aug 24;14(9):1762. doi: 10.3390/pharmaceutics14091762. Pharmaceutics. 2022. PMID: 36145510 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
